Naujausios naujienos ir straipsniai apie genetinius tyrimus
May 5, 2026
Recent research suggests that a widely used painkiller may have an impact on cancer risk. Studies have found a potential link between long-term use of this medication and changes in cancer incidence.
May 5, 2026
University of Kent. "Scientists discover skincare compound that kills drug-resistant bacteria." ScienceDaily. ScienceDaily, 21 April 2026. <www.sciencedaily.com/releases/2026/04/260420014738.htm>...
May 5, 2026
University of Kent. "Scientists discover skincare compound that kills drug-resistant bacteria." ScienceDaily. ScienceDaily, 21 April 2026. <www.sciencedaily.com/releases/2026/04/260420014738.htm>...
May 4, 2026
Researchers at the University of California - Riverside have developed an oxygen-releasing gel that may help prevent amputations in patients with diabetic wounds. The gel, which delivers a consistent supply of oxygen to affected areas, has shown promising results in preclinical studies.
May 4, 2026
Researchers at the University of Kent have identified a compound commonly used in skincare products that demonstrates potent antibacterial properties, particularly against bacteria resistant to traditional antibiotics. This discovery may lead to new treatments for infections caused by drug-resistant pathogens.
May 4, 2026
Researchers have discovered micro- and nano-plastics within arterial plaque samples taken from patients with cardiovascular disease. The presence of these plastics suggests a potential link between plastic pollution and human health.
May 4, 2026
Researchers at NYU Langone Health have developed a gene-based blood test that may detect early signs of melanoma recurrence. This non-invasive test has shown promise in identifying patients who are at high risk of cancer returning.
May 4, 2026
NYU Langone Health / NYU Grossman School of Medicine. "Gene-based blood test for melanoma may catch early signs of cancer's return." ScienceDaily. ScienceDaily, 16 April 2025. <www.sciencedaily.com...
May 4, 2026
Researchers at Chiba University have made a breakthrough in treating refractory skin cancer using targeted alpha therapy. This innovative approach shows potential for improving treatment outcomes for patients with resistant skin cancer.
